CN-121362668-B - Composite probiotics for reducing generation of harmful gas in intestinal tract and regulating intestinal flora

Abstract

The invention relates to the technical field of microorganisms, in particular to a compound probiotic for reducing the generation of harmful gas in intestinal tracts and regulating intestinal flora. The composite probiotics provided by the invention consist of bifidobacterium animalis subspecies Bi66, lactobacillus plantarum P16 and saccharomyces boulardii Bld-3 strains. The three bacteria are combined, so that the content of short-chain fatty acid in intestinal flora can be obviously increased, the yield of beneficial gases such as CH 4 、H 2 and the like is increased, the yield of NH 3 、H 2 S harmful to human bodies is reduced, beneficial bacteria are promoted, the growth of harmful bacteria is inhibited, and the intestinal flora is regulated. Under the condition of keeping the consistent using amount of bacteria, compared with the strain intervention mode of deleting any one of the bacteria, the combination of the three bacteria has the best effect in improving the intestinal flora, which indicates that the three bacteria can cooperate and promote each other and can synergistically improve the intestinal flora.

Inventors

• XIONG TAO
• WANG YINGYING
• ZHANG YAN
• CHEN ZHIXIAN
• ZHANG XIAOLI
• SUN JIN

Assignees

• 安琪酵母股份有限公司
• 安琪纽特股份有限公司

Dates

Publication Date

20260505

Application Date

20251219

Claims (15)

1. 1. A composite bacterium is characterized by comprising bifidobacterium animalis subspecies Bi66, lactobacillus plantarum P16 and saccharomyces boulardii Bld-3; the ratio of the bifidobacterium animalis subspecies of Bi66, the lactobacillus plantarum P16 and the live bacteria number of the saccharomyces boulardii Bld-3 is 1:1:1, 5:1:1 or 1:2:5; the preservation number of the bifidobacterium animalis subspecies of milk Bi66 is CCTCC NO: M2023769; the preservation number of the lactobacillus plantarum P16 is CCTCC NO: M2023767; the preservation number of the saccharomyces boulardii Bld-3 is CCTCC NO: M20251803.
2. 2. The complex bacteria of claim 1, wherein the total number of viable bacteria in the complex bacteria is not less than 1X 10 8 CFU/ml or 1X 10 8 CFU/g.
3. 3. Use of a complex bacterium according to claim 1 or 2 for the preparation of a probiotic according to any one of the following; (I) Increasing the content of short chain fatty acids, in particular acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, in the intestinal flora; (II) increase the yield of beneficial gas CH 4 and/or H 2 ; (III) reducing the production of harmful gases NH 3 and/or H 2 S, or (IV) an effect of regulating intestinal flora that promotes the growth of beneficial bacteria of bifidobacterium animalis, lactobacillus reuteri or clostridium tenella and inhibits harmful bacteria of escherichia coli and/or salmonella.
4. 4. The use of claim 3, wherein the probiotic preparation comprises a composite probiotic preparation or a synbiotic preparation.
5. 5. The use of claim 4, wherein the probiotic composition comprises a food product, a feed product or a feed additive.
6. 6. The use according to claim 5, wherein the food product is a health food product, a special medical use food product, a functional food product or a pet food product.
7. 7. The use according to claim 5, wherein the formulation of the probiotic is a powder, granule, capsule, tablet, pill, extract or liquid formulation.
8. 8. A microecological product comprising the complex bacterium according to claim 1 or 2.
9. 9. The probiotic preparation of claim 8, wherein said probiotic preparation comprises a composite probiotic preparation or a synbiotic preparation.
10. 10. The probiotic article of claim 8, wherein said probiotic article comprises a food product, a feed product, or a feed additive.
11. 11. The probiotic product of claim 10, wherein said food product is a health food product, a special medical use food product, a functional food product or a pet food product.
12. 12. The probiotic according to claim 8, wherein the formulation of said probiotic is a powder, granule, capsule, tablet, pill, extract or liquid formulation.
13. 13. The probiotic according to claim 12, characterized in that said powder comprises a freeze-dried powder; The preparation method of the freeze-dried powder comprises the following steps: Step 1, respectively activating and culturing the bifidobacterium animalis subspecies Bi66 and the lactobacillus plantarum P16 to obtain bacterial liquid, centrifugally filtering and collecting bacterial bodies, mixing the bacterial liquid with a protective agent, and freeze-drying to respectively obtain Bi66 bacterial powder and P16 bacterial powder; Step 2, activating and culturing the saccharomyces boulardii Bld-3 to obtain seed fermentation liquor, centrifugally collecting thalli, mixing with an emulsifying agent, vegetable oil and starch, and granulating to obtain saccharomycete powder; And 3, compounding the Bi66 bacteria powder prepared in the step 1, the P16 bacteria powder and the saccharomycete powder prepared in the step 2 according to a proportion to obtain the freeze-dried powder.
14. 14. The microecological article of claim 13, wherein the number of viable bacteria in the Bi66 powder is 6000 million CFU/g; the viable count in the P16 bacterial powder is 2000 hundred million CFU/g; the saccharomyces boulardii in the saccharomycete powder is 200 hundred million CFU/g.
15. 15. The method of preparing a probiotic composition according to claim 13, wherein said lyophilized powder comprises the steps of: Inoculating the bifidobacterium animalis subspecies Bi66 and the lactobacillus plantarum P16 into an MRS liquid culture medium respectively, culturing for 24 hours at 37 ℃ for activation, and continuously activating for 2 times to obtain an activation solution; step 1-2, inoculating the activating solution into MRS liquid culture medium according to an inoculum size of 3% (v/v), and culturing for 22 hours at 37 ℃ to obtain bacterial solution; Step 1-3, centrifuging the bacterial liquid for 10min at the temperature of 4 ℃ and 8000r/min, and filtering to obtain bacterial cells; Step 1-4, mixing the thalli with a protective agent with the mass of 5 times to obtain bacterial suspension; step 1-5, pre-culturing the bacterial suspension for 1h at 37 ℃ and then freeze-drying for 24h to obtain Bi66 bacterial powder and P16 bacterial powder; Step 2-1, inoculating the saccharomyces boulardii Bld-3 into a liquid culture medium, and culturing for 26 hours at 37 ℃ for activation to obtain an activation liquid; Step 2-2, inoculating the activation solution into a liquid culture medium, and culturing for 24 hours at 30 ℃ to obtain seed fermentation liquor; step 2-3, centrifugally separating the seed fermentation liquor to obtain yeast cells; Step 2-4, adding an emulsifying agent and vegetable oil into the yeast cells, adding starch, and granulating to obtain yeast powder; And 3, compounding the Bi66 bacteria powder prepared in the step 1, the P16 bacteria powder and the saccharomycete powder prepared in the step 2 according to a proportion to obtain the freeze-dried powder.

Description

Composite probiotics for reducing generation of harmful gas in intestinal tract and regulating intestinal flora Technical Field The invention relates to the technical field of microorganisms, in particular to a compound probiotic for reducing the generation of harmful gas in intestinal tracts and regulating intestinal flora. Background The human intestinal tract contains a huge number and variety of microflora, collectively known as intestinal flora. Numerous scientific studies have demonstrated that the composition and functional balance of the intestinal flora is closely related to human health. The balanced intestinal flora not only contributes to food digestion, nutrient absorption and vitamin synthesis, but also plays a vital role in maintaining intestinal barrier function, regulating immune system, resisting pathogen invasion, affecting metabolism, neuromodulation and the like. In addition, harmful gases generated by metabolism of intestinal flora not only can cause uncomfortable symptoms such as abdominal distension, abdominal pain and halitosis, but also can cause toxicity to intestinal cells when excessive, influence the barrier function of the intestinal tract, and even are closely related to the occurrence and development of certain intestinal diseases. Intestinal dysbacteriosis is thought to be associated with the development of a variety of diseases, such as Irritable Bowel Syndrome (IBS), inflammatory Bowel Disease (IBD), antibiotic-associated diarrhea (AAD), constipation, and the like. Intestinal dysregulation is often accompanied by excessive proliferation of harmful bacteria, reduced beneficial bacteria and excessive production of harmful metabolites, including the above-mentioned harmful gases. Thus the dynamic balance of intestinal flora is critical for the health of the individual. Probiotics act as a living microorganism that when ingested in sufficient quantities produces beneficial effects on host health. The current regulation and improvement of intestinal flora structure by exogenous supplementation of probiotics has become an important strategy for the prevention and adjuvant treatment of related diseases. There are various probiotic products on the market at present, including single strain or combination of strains (composite microbial inoculum), and dosage forms comprise medicines, health products, foods (such as yoghurt, fermented milk, probiotic powder) and the like. Although probiotics are widely applied, the probiotics preparation in the prior art especially relates to the combination of multiple strains, has the defects of collocation randomness and synergy, and particularly, the research on realizing the synergistic reduction of intestinal harmful gas through the combination of specific strains has been rarely reported. Therefore, there is an urgent need to develop a novel compound probiotic, which has a synergistic effect based on a specific strain combination, and can effectively overcome the defects of the prior art, and realize a more comprehensive and efficient flora balance effect. Although the regulation of intestinal flora by probiotics has been widely studied, the probiotics of the prior art, especially when multi-strain combinations are involved, still have significant limitations. If the efficacy of a single strain is limited, the combination of multiple strains has the randomness of collocation and the lack of synergistic effect, and especially the report of remarkably reducing various intestinal harmful gases is limited. The prior art discloses a compound probiotics capable of relieving ulcerative colitis, a preparation method and application thereof, wherein the compound probiotics comprise bifidobacterium bifidum Bifidobacterium longum BL, bifidobacterium animalis subspecies Bifidobacterium animalis subs p, lactis Bla80 and lactobacillus casei Lactobacillus casei LC, the preparation method comprises the following steps of respectively preparing bifidobacterium longum Bifidobacterium longum BL, bifidobacterium animalis subspecies Bifidobacterium animalis subsp, lactobacillus Bla80 and lactobacillus casei Lactobacillus casei LC89 freeze-dried powder, and uniformly mixing the three freeze-dried powders according to a proportion to prepare the compound probiotics. The compound probiotics provided by the invention can prevent and/or treat ulcerative colitis, and has a great application prospect in preparing products (such as solid beverages) for preventing and/or treating ulcerative colitis. The probiotic agent for increasing immunity and improving intestinal flora and application thereof are characterized in that five specific bifidobacteria strains of different types are compounded, potential interactions exist among the five strains, the five strains can be mutually matched, the synergistic effect is achieved in the aspects of promoting the growth of immune organs and increasing the total quantity and diversity of intestinal flora, the probiotic agent is match